A/Reissue



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

OX REISSUE

**Assistant Commissioner of Patents** Washington, D.C. 20231

## REISSUE APPLICATION TRANSMITTAL

Transmitted herewith is the application for reissue of U.S.									
	$\boxtimes$	Utility	Patent		Plant Patent		] ]	Design Patent	
No.: US 5,698,197			issued on December 16, 1997						
	Inventor(s):		Founds et al.						
	Title:		MONOCLONAL ANTIBODY SPECIFIC FOR ADVANCED GLYCOSYLATION ENDPRODUCTS IN BIOLOGICAL SAMPLES						
	Enclosed are the following:								
I.	Specif	ication a	and claim(s) (37 C.F.R. § 1.173)						
	A.	∑ 22	page(s) of	specification	on (including tit	le page)			
		∑ 2	page(s) of	claims					
		$\boxtimes 1$	page(s) of	abstract					
		⊠ 7	page(s) of	drawings					

## **CERTIFICATION UNDER 37 C.F.R. § 1.10**

I hereby certify that this Reissue Application Transmittal and the documents referred to as enclosed therein are being deposited with the United States Postal Service, in an envelope as "Express Mail Post Office to Addressee," mailing Label Number EL 093 228 402 US, addressed to the: BOX REISSUE, Assistant Commissioner for Patents, Washington, D.C. 20231, on December 16, 1999.

Suzanne M. Zalot

II.	Decla	Declaration and power of attorney						
	$\boxtimes$	3 pages of declaration and power of attorney (executed).						
III.	Prelin	ninary amendment						
		Attached						
IV.	Offer to surrender the original letters patent in accordance with 37 C.F.R. § 1.17 enclosed along with:							
		consent of assignee.						
		copy of assignment enclosed						
		Offer to surrender is by the assignee of the entire interest attached.						
		A certificate under 37 CFR 3.73(b) is attached						
V.	Letter	s patent						
		Original letters patent are attached.						
		Declaration that original letters patent lost or inaccessible is attached.						
	$\boxtimes$	A copy of the original printed patent is attached.						
VI.	Petitio	tition to proceed without assignee's assent.						
		Attached hereto is a "PETITION TO PROCEED WITH REISSUE APPLICATION WITHOUT ASSIGNEE'S ASSENT".						
VII.	Information Disclosure Statement							
		Attached						
•		Copies of the IDS citation(s) is/are attached.						
VIII.	$\boxtimes$	Applicant Claims the priority of US Application Serial No. 08/367,507 filed December 30, 1994 entitled A MONOCLONAL ANTIBODY SPECIFIC FOR ADVANCED GLYCOSYLATION ENDPRODUCTS IN BIOLOGICAL SAMPLES.						

	IX.	Priority-35 U.S.C. § 119 (foreign priority)
		Priority of application Application No, filed on, in is claimed under 35 U.S.C. § 119.
		The certified copy has been filed in prior application Application No. 0 /, filed on
	X.	Basic Filing Fee Calculation (37 C.F.R. § 1.16(h), (i) and (j))
	indepe	The reissue application presents, for fee calculation purposes, 23 total claims; 3 endent claims and 2 multiple-dependent claims that account for 9 claims.
		The basic filing fee under under 37 CFR 1.16(h) is \$760.00 3 Additional Claims @ \$18.00 =\$54.00 Total Fee Enclosed \$814.00
	XI.	Small Entity Status (if applicable)
		A statement that this filing is by a small entity is attached. will be forwarded.
	XII.	Additional Fee Payments
		Payment is being made for "PETITION TO PROCEED WITH REISSUE APPLICATION WITHOUT ASSIGNEE" (37 C.F.R. § 1.17(h))
	XIII.	Authorization To Charge Additional Fees
•	in the p 0480.	The Commissioner is hereby authorized to charge any additional fees not included payment made herewith, but required to obtain a filing date to Deposit Account No. 04-
	XIV.	This reissue application is being filed because the patentee claimed less than the patentee right to claim. As a result, this reissue application contains claims that are broader than the

claims of US Patent No. 5,698,197. This reissue application is timely filed within two years of

the issuance of US Patent No. 5,698,197 on 16 December 1997.